Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | DRD1 | P21728 | 2/20 | 0.36 |
| ▸ | HHAT | Q5VTY9 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29970524 | 0.84 | SMN1; SMN2 (0.37) | SMN1; SMN2DRD1HHATKMT2ANPC1 | |
| SCHEMBL22688218 | 0.81 | NR1H2 (0.35) | SMN1; SMN2KMT2ANPC1KDM4E | |
| SCHEMBL20912505 | 0.78 | HHAT (0.51) | HHATNPC1TRPV1ALDH1A1 | |
| SCHEMBL22688406 | 0.74 | L3MBTL1 (0.33) | — | |
| SCHEMBL29970949 | 0.74 | DRD1 (0.59) | DRD1HHATKMT2A | |
| SCHEMBL29971109 | 0.73 | STAT3 (0.44) | ALDH1A1 | |
| SCHEMBL19951727 | 0.69 | SMN1; SMN2 (0.46) | SMN1; SMN2KMT2ANPC1POLBKDM4E | |
| SCHEMBL20912504 | 0.68 | HHAT (0.46) | HHATNPC1TRPV1ALDH1A1 | |
| SCHEMBL6648069 | 0.68 | PNMT (0.34) | SMN1; SMN2 | |
| SCHEMBL16794359 | 0.67 | ADORA1 (0.37) | SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3746444-B1 | CYCLOALKYL SUBSTITUTED PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST RSV | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2023-09-27 | — | — | EP | disclosed |
| US-11491157-B2 | Cycloalkyl substituted pyrazolopyrimidines having activity against RSV | Janssen Sciences Ireland Unlimited Company Co Cork, IE (IE) | 2022-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11491157-B2 | Cycloalkyl substituted pyrazolopyrimidines having activity against RSV | ACE, ACE2, PTBP1 | SMN1; SMN2 558/4885DRD1 3977/4885HHAT 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.